A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 39/395 (2006.01) A61K 51/10 (2006.01) A61P 35/02 (2006.01) C07K 16/28 (2006.01)
Patent
CA 2390412
The invention discloses compositions, combination therapies and methods of treating B-cell lymphomas and leukemias, as well as other CD40+ malignancies. The primary active agent of the composition is an anti-CD40L antibody or other CD40L antagonist that inhibits CD40-CD40L interaction. Compositions may additionally contain or utilize any one or more of the following in combination for the treatment of said disease: anti-CD20 antibodies, chemotherapeutic agents, chemotherapy cocktails, and radiotherapy.
L'invention concerne des compositions, une combinaison de thérapies, et des méthodes de traitement des lymphomes des cellules B et des leucémies ainsi que d'autres tumeurs malignes CD40+. L'agent actif primaire de la composition est un anticorps anti-CD40L ou un antagoniste CD40L qui inhibe l'interaction CD40-CD40L. Les compositions peuvent en outre contenir ou utiliser au moins l'une des combinaisons de traitement suivantes: anticorps anti-CD20, agents de chimiothérapie, cocktails de chimiothérapie, et radiothérapie.
Hanna Nabil
Hariharan Kandasamy
Biogen Idec Inc.
Gowling Lafleur Henderson Llp
Idec Pharmaceuticals Corporation
LandOfFree
Treatment of b cell malignancies using anti-cd40l antibodies... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of b cell malignancies using anti-cd40l antibodies..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of b cell malignancies using anti-cd40l antibodies... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1758917